Exclusion Criteria:~* Significant neurological disorder other than AD (e.g. hypoxia, stroke, traumatic brain
injury~* Significant neurodegenerative diseases, other than AD, and causes of dementias, Parkinson's disease
and Huntington's disease, vascular dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP
(Progressive Supranuclear Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure
hydrocephalus).~* Meeting Diagnostic Criteria for Possible AD according to workgroups of the Diagnostic
Guidelines of the NIA-AA.~* A current diagnosis of uncontrolled Type I or Type II diabetes mellitus, as defined
by Hemoglobin A1C (Hb A1C â‰¥ 8).~* A current active, uncontrolled seizure disorder.~* Diagnosis of cancer,
except for those participants who have undergone potentially curative therapy with no evidence of recurrence
for > 5 years.~* History of alcoholism or substance abuse, current or within past 5 years.~* Previous exposure
to Benfotiamine within past 3 months.~* Contraindication to MRI.~* Participation in another clinical trial for
an investigational agent and having taken at least one dose of study drug, unless confirmed as having been on
placebo, within 4 weeks prior to the baseline visit. The end of a previous investigational trial is defined as
the date of the last dose of an investigational agent.~* Initiation of a monoclonal antibody treatment
targeting brain amyloid within 6 months prior to the baseline visit.~* A disability that may prevent the
patient from completing all study requirements e.g.,blindness, deafness, severe language difficulty).
